Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory mantle cell lymphoma after at least two systemic treatment lines, including a BTK inhibitor.
LAMPGEN ANALYSIS
Why it matters
The approval introduced a noncovalent BTK inhibitor after prior BTK-directed treatment.
What research teams should watch
Verify previous BTK inhibitor exposure and track the FDA status of this accelerated indication separately from CLL.
PRIMARY RECORDS